MicroRNAs as Diagnostic and Predictive Biomarkers for Acute Graft Versus Host Disease

Recruiting in Palo Alto (17 mi)

Overseen by Cheryl Mensah, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Northwell Health

No Placebo Group

Trial Summary

What is the purpose of this trial?

The goal of this research proposal is to identify a miRNA expression profile as a biomarker to diagnose and predict acute graft versus host disease (aGVHD) in patients who undergo allogeneic transplantation. This biomarker, once identified, will need validation in larger cohorts.

Eligibility Criteria

Inclusion Criteria

Patients undergoing fully matched allogeneic PBCSC and bone marrow transplantation who present with clinical signs and symptoms of grade II- IV aGVHD within 100 days after transplantation as defined by skin, GI, and/or liver involvement that are confirmed by biopsy, regardless of age

Patients undergoing a matched, unrelated donor (8/8) or matched, related donor transplant (6/6)

Allogeneic transplant is from donor's peripheral blood stem cells or bone marrow transplant

Participant Groups

Group I: non aGVHD Experimental Treatment 0 Interventions

Patients who undergo allogeneic transplant but do not develop aGVHD.

Group II: aGVHD Experimental Treatment 1 Intervention

Patient who undergo allogeneic transplant with clinical and/or biopsy-proven diagnosis of aGVHD within the first 100 days post-transplant.

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Monter Cancer Center Lake Success, NY

Who Is Running the Clinical Trial?

Northwell Health Lead Sponsor

References